Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (ESPR) Stock Overview
Explore Esperion Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
687.4M
P/E Ratio
-6.50
EPS (TTM)
$-0.54
ROE
0.25%
ESPR Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Esperion Therapeutics, Inc. (ESPR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 51.23, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $3.43.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -6.50 and a market capitalization of 687.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.